← Oncology Approval Tracker

FDA DECISION ·

Orgovyx

relugolix · Myovant Sciences

FDA approvalNew therapyProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced prostate cancer.

LAMPGEN ANALYSIS

Why it matters

Introduced oral gonadotropin-releasing hormone receptor antagonism as an androgen deprivation option.

What research teams should watch

Make daily adherence and interacting medicines part of follow-up and track testosterone suppression.

PRIMARY RECORDS

Sources